These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 17055272)

  • 61. Efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type 2 diabetes.
    Scott R; Wu M; Sanchez M; Stein P
    Int J Clin Pract; 2007 Jan; 61(1):171-80. PubMed ID: 17156104
    [TBL] [Abstract][Full Text] [Related]  

  • 62. A novel dipeptidyl peptidase-4 inhibitor, alogliptin (SYR-322), is effective in diabetic rats with sulfonylurea-induced secondary failure.
    Asakawa T; Moritoh Y; Kataoka O; Suzuki N; Takeuchi K; Odaka H
    Life Sci; 2009 Jul; 85(3-4):122-6. PubMed ID: 19427871
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Piperidinyl-2-phenethylamino inhibitors of DPP-IV for the treatment of type 2 diabetes.
    Benbow JW; Andrews KA; Aubrecht J; Beebe D; Boyer D; Doran S; Homiski M; Hui Y; McPherson K; Parker JC; Treadway J; Vanvolkenberg M; Zembrowski WJ
    Bioorg Med Chem Lett; 2009 Apr; 19(8):2220-3. PubMed ID: 19285862
    [TBL] [Abstract][Full Text] [Related]  

  • 64. [Dipeptidylpeptidase IV inhibitors and dual action PPAR-agonists].
    Heinzl S
    Med Monatsschr Pharm; 2006 Mar; 29(3):93-6. PubMed ID: 16550882
    [No Abstract]   [Full Text] [Related]  

  • 65. Synthesis and biological evaluation of pyrrolidine-2-carbonitrile and 4-fluoropyrrolidine-2-carbonitrile derivatives as dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes.
    Wang J; Feng Y; Ji X; Deng G; Leng Y; Liu H
    Bioorg Med Chem; 2013 Dec; 21(23):7418-29. PubMed ID: 24153396
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Dipeptidyl peptidase IV inhibitors for the treatment of diabetes.
    Weber AE
    J Med Chem; 2004 Aug; 47(17):4135-41. PubMed ID: 15293982
    [No Abstract]   [Full Text] [Related]  

  • 67. Synthesis of novel potent dipeptidyl peptidase IV inhibitors with enhanced chemical stability: interplay between the N-terminal amino acid alkyl side chain and the cyclopropyl group of alpha-aminoacyl-l-cis-4,5-methanoprolinenitrile-based inhibitors.
    Magnin DR; Robl JA; Sulsky RB; Augeri DJ; Huang Y; Simpkins LM; Taunk PC; Betebenner DA; Robertson JG; Abboa-Offei BE; Wang A; Cap M; Xin L; Tao L; Sitkoff DF; Malley MF; Gougoutas JZ; Khanna A; Huang Q; Han SP; Parker RA; Hamann LG
    J Med Chem; 2004 May; 47(10):2587-98. PubMed ID: 15115400
    [TBL] [Abstract][Full Text] [Related]  

  • 68. [DPP-4 inhibition raises incretin levels].
    Warpakowski A
    Med Monatsschr Pharm; 2006 Aug; 29(8):311-2. PubMed ID: 16927605
    [No Abstract]   [Full Text] [Related]  

  • 69. Synthesis and SAR of azolopyrimidines as potent and selective dipeptidyl peptidase-4 (DPP4) inhibitors for type 2 diabetes.
    Brigance RP; Meng W; Fura A; Harrity T; Wang A; Zahler R; Kirby MS; Hamann LG
    Bioorg Med Chem Lett; 2010 Aug; 20(15):4395-8. PubMed ID: 20598534
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Sitagliptin treatment of patients with type 2 diabetes does not affect CD4+ T-cell activation.
    White PC; Chamberlain-Shea H; de la Morena MT
    J Diabetes Complications; 2010; 24(3):209-13. PubMed ID: 19854074
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Discovery of potent, selective, and orally bioavailable oxadiazole-based dipeptidyl peptidase IV inhibitors.
    Xu J; Wei L; Mathvink RJ; Edmondson SD; Eiermann GJ; He H; Leone JF; Leiting B; Lyons KA; Marsilio F; Patel RA; Patel SB; Petrov A; Scapin G; Wu JK; Thornberry NA; Weber AE
    Bioorg Med Chem Lett; 2006 Oct; 16(20):5373-7. PubMed ID: 16919457
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Discovery, SAR, and X-ray structure of novel biaryl-based dipeptidyl peptidase IV inhibitors.
    Qiao L; Baumann CA; Crysler CS; Ninan NS; Abad MC; Spurlino JC; Desjarlais RL; Kervinen J; Neeper MP; Bayoumy SS; Williams R; Deckman IC; Dasgupta M; Reed RL; Huebert ND; Tomczuk BE; Moriarty KJ
    Bioorg Med Chem Lett; 2006 Jan; 16(1):123-8. PubMed ID: 16236500
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Discovery of potent, selective, and orally bioavailable quinoline-based dipeptidyl peptidase IV inhibitors targeting Lys554.
    Maezaki H; Banno Y; Miyamoto Y; Moritoh Y; Asakawa T; Kataoka O; Takeuchi K; Suzuki N; Ikedo K; Kosaka T; Sasaki M; Tsubotani S; Tani A; Funami M; Yamamoto Y; Tawada M; Aertgeerts K; Yano J; Oi S
    Bioorg Med Chem; 2011 Aug; 19(15):4482-98. PubMed ID: 21741847
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Potent and selective proline derived dipeptidyl peptidase IV inhibitors.
    Edmondson SD; Mastracchio A; Beconi M; Colwell LF; Habulihaz B; He H; Kumar S; Leiting B; Lyons KA; Mao A; Marsilio F; Patel RA; Wu JK; Zhu L; Thornberry NA; Weber AE; Parmee ER
    Bioorg Med Chem Lett; 2004 Oct; 14(20):5151-5. PubMed ID: 15380217
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Discovery of DA-1229: a potent, long acting dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes.
    Kim HJ; Kwak WY; Min JP; Lee JY; Yoon TH; Kim HD; Shin CY; Kim MK; Choi SH; Kim HS; Yang EK; Cheong YH; Chae YN; Park KJ; Jang JM; Choi SJ; Son MH; Kim SH; Yoo M; Lee BJ
    Bioorg Med Chem Lett; 2011 Jun; 21(12):3809-12. PubMed ID: 21570283
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Xanthine mimetics as potent dipeptidyl peptidase IV inhibitors.
    Kurukulasuriya R; Rohde JJ; Szczepankiewicz BG; Basha F; Lai C; Jae HS; Winn M; Stewart KD; Longenecker KL; Lubben TW; Ballaron SJ; Sham HL; von Geldern TW
    Bioorg Med Chem Lett; 2006 Dec; 16(24):6226-30. PubMed ID: 17010607
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Discovery of potent dipeptidyl peptidase IV inhibitors derived from β-aminoamides bearing substituted [1,2,3]-triazolopiperidines for the treatment of type 2 diabetes.
    Shan Z; Peng M; Fan H; Lu Q; Lu P; Zhao C; Chen Y
    Bioorg Med Chem Lett; 2011 Mar; 21(6):1731-5. PubMed ID: 21334204
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Discovery of JANUVIA (Sitagliptin), a selective dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.
    Thornberry NA; Weber AE
    Curr Top Med Chem; 2007; 7(6):557-68. PubMed ID: 17352677
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Aryl- and heteroaryl-substituted aminobenzo[a]quinolizines as dipeptidyl peptidase IV inhibitors.
    Boehringer M; Fischer H; Hennig M; Hunziker D; Huwyler J; Kuhn B; Loeffler BM; Luebbers T; Mattei P; Narquizian R; Sebokova E; Sprecher U; Wessel HP
    Bioorg Med Chem Lett; 2010 Feb; 20(3):1106-8. PubMed ID: 20031408
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Synthesis, evaluation and molecular docking of thiazolopyrimidine derivatives as dipeptidyl peptidase IV inhibitors.
    Sharma M; Gupta M; Singh D; Kumar M; Kaur P
    Chem Biol Drug Des; 2012 Dec; 80(6):918-28. PubMed ID: 22943413
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.